Objective. To study the impact of disease and treatment with DMARDs on antibody response elicited by either pneumococcal conjugate vaccine (PCV13) or pneumococcal polysaccharide vaccine (PPV23) in patients with SSc.
Introduction
Infections caused by Streptococcus pneumoniae including community-acquired pneumonia and invasive pneumococcal disease (IPD) account for considerable morbidity and mortality in individuals with underlying immunocompromising diseases [1] . Population-based surveillance for IPD (19952012) in Toronto, Canada, showed that 28% of episodes of IPD occurred in immunocompromised individuals. The risk of IPD in these individuals was 2.12.7 higher compared with immunocompetent controls. Five years after implementation of a publicly funded vaccination program using pneumococcal polysaccharide vaccine (PPV23) the incidence rate ratio decreased to 0.57 [1] .
Current EULAR evidence-based recommendations advise that vaccination with a single dose of PPV23 should be strongly considered in all patients with rheumatic diseases [2] . The Centres for Disease Control and Prevention Advisory Committee on Immunization Practice recommends immunization with a dose of 13-valent pneumococcal conjugate vaccine (PCV13) followed by a dose of PPV23 in adults with immunocompromising conditions [3] .
SSc (scleroderma) is a chronic inflammatory rheumatic disease characterized by endothelial and fibroblast dysfunction [4] . Compared with the normal population, patients with SSc have an increased mortality, and pulmonary involvement-with interstitial lung disease or pulmonary arterial hypertension being the most common-accounts for a large part of this increased mortality [5, 6] . Many of these patients with interstitial lung disease or pulmonary arterial hypertension have a critical situation when they encounter a severe infection. Data from the longstanding Oxford Record Linkage Study (19632008) showed that compared with controls, patients with SSc had an increased risk ratio of 4.2 for being admitted to hospital for a pneumococcal disease [7] . Similarly, among SSc patients admitted to the Khon Kaen University Hospital, Thailand, infections were the most common indication for hospitalization, with 60% of infections being pneumonia [8] . In addition, an increased mortality rate was found in a study from the UK where infection, mainly pneumonia, was the leading cause of death [9] .
Studies investigating the immunogenicity of pneumococcal vaccine in patients with SSc are scarce. A dose of PPV23 was found to be immunogenic in a study comprising 18 patients with SSc, 8 of whom were treated with DMARDs [10] . To date, there are no data on antibody response following vaccination with PCV13 in SSc patients. There are no data comparing the immunogenicity of PPV23 and PCV13 in these patients.
The aim of the present study was to investigate the impact of SSc disease and treatment with DMARDs on antibody response elicited by either pneumococcal conjugate (PCV13) or polysaccharide (PPV23) vaccine in patients with SSc compared with healthy controls. In addition, the aim was to monitor the safety of these vaccines.
Methods
Patients with SSc, regularly followed at the Department of Rheumatology, Skå ne University Hospital in Lund, Sweden, were consecutively offered participation in the study. Only vaccine-naïve patients or those who were immunized against pneumococci >5 years earlier were eligible for the study. Controls were recruited among the staff at the rheumatology department or their acquaintances. The first 13 patients received a single dose of PPV23 intramuscularly, and after PCV13 was licensed for adults in Sweden the following 31 patients were vaccinated using this vaccine.
At vaccination, all patients were assessed by a rheumatologist and their medical records were scrutinized in order to ensure fulfilment of classifications criteria for SSc [11] . The clinical assessment was performed as a regular follow-up visit including monitoring of disease activity, calculation of modified Rodnan skin score, previous and ongoing medications, comorbidities and vaccination status [12] . At vaccination, data on smoking habits were collected and all participants were asked to answer to the HAQ [13] .
Serum samples were collected immediately before vaccination and 46 weeks after vaccination. All participants were instructed to be vigilant about adverse events and received a form for recording suspected adverse effects and possible impact of the vaccination on the rheumatic disease. The patients' written reports on possible side effects were collected at the time of blood sample drawing after vaccination.
Antibody response
Levels of serotype-specific pneumococcal IgG to serotypes 23 F and 6B were measured using the WHO standard ELISA for quantitation of human IgG antibodies specific for S. pneumoniae capsular polysaccharides (Pn PS ELISA), as previously described [14] . The assay was calibrated with an international reference serum [15] . The lower limit of detection was 0.01 mg/l. A positive vaccine antibody response was defined as a 52-fold increase in pre-vaccination specific antibody level. Antibody levels 51 mg/l were considered protective.
Opsonophagocytic assay
The functionality of the antibodies, that is, the ability to opsonize bacteria for phagocytosis, was performed on pneumococci of serotype 23 F using sera collected before and 46 weeks after vaccination. The method was previously described by Martinez et al. [16] but was executed with some modifications [17, 18] . In short, pneumococci obtained from Statens Serum Institut (Copenhagen, Denmark) were cultured, killed and labelled with FITC. FITC-labelled pneumococci were incubated with diluted heat-inactivated serum, followed by addition of baby rabbit serum and subsequent further incubation at 37 C in buffer supporting complement activation. Polymorphonuclear neutrophils from healthy donors were preincubated with phycoerythrin (PE)-labelled anti-CD66 antibodies and subsequently added to the opsonized bacteria. Samples were analysed with BD Accuri C6 flow cytometry (BD Biosciences, Sweden) using fixed gating. Results were expressed as percentage of cells (PE-positive events) showing uptake of bacteria (events positive for both PE and FITC). Inter-assay variation was compensated for by adjusting values to mean value of a serum with high opsonizing ability. A negative control consisting of bacteria preincubated only with BSA was included.
Ethical considerations
The study complies with the Declaration of Helsinki. Ethical approval was obtained from the Regional Ethical Review Board at Lund University, Lund, Sweden (Dnr 2011/341). Oral and written consent was obtained from each participant before inclusion in the study.
Statistical analysis
Geometric mean levels (95% CI) were calculated from log transformed pre-and post-vaccination antibody levels and compared using Wilcoxon signed ranks test. Preand post-vaccination antibody levels between patients and controls were compared using KruskalWallis test. Differences between groups were calculated using Chisquare or MannWhitney U test when appropriate.
Results
In total, 44 patients with SSc (32 without DMARDs and 12 on DMARDs) and 49 controls were immunized. Table 1 summarizes the demographics, disease and treatment characteristics at vaccination.
Pre-vaccination antibody levels to both serotypes did not differ between the three groups. After vaccination, antibody levels for both serotypes increased significantly in SSc without DMARDs and controls (P < 0.001), but among SSc on DMARDS the significant increase was only seen for serotype 6B (P = 0.041 for 6B and P = 0.110 for 23 F). Compared with SSc without DMARDs, patients with SSc treated with DMARDs had lower post-vaccination antibody levels, mean fold increase in antibody concentration and percentage of patients reaching putative protective antibody levels for both serotypes. There was no significant difference in post-vaccination antibody levels between SSc patients without DMARDs and controls.
Fig . 1A and B shows the pre-and post-vaccination antibody levels for serotype 6B and 23 F with a line connecting pre-and post-vaccination values on the individual patient level in each group. Fig. S1 , available as supplementary data at Rheumatology online, shows the percentage of patients with positive antibody response to serotype 6B, 23 F or both serotypes, regardless of vaccine type.
SSc patients receiving DMARDs had a lower percentage of responders compared with SSc without DMARDs and controls. The same pattern with a lower proportion of responders in SSc on DMARDs was seen in patients immunized with PPV13 or PCV23 (Figs S2 and S3, available as supplementary data at Rheumatology online).
When pre-and post-vaccination antibody levels for 6B and 23 F were compared between individuals immunized with PCV13 and those immunized with PPV23, no significant difference was seen within the same treatment group or within the whole study population (Table S1 , available as supplementary data at Rheumatology online).
Before vaccination, there were no statistically significant differences in opsonophagocytic assay (OPA) between the groups. OPA of serotype 23 F showed a significant increased uptake of bacteria after vaccination compared with uptake prior to vaccination in both patient groups and controls, but was most pronounced in controls (Fig. 1C) . Post-vaccination OPA results were higher in controls compared with SSc without DMARDs (P = 0.009 but not compared with SSc on DMARDs (P = 0.189). The difference in post-vaccination OPA between SSc patients with or without DMARD was not significant (P = 0.165).
Age at vaccination did not correlate with pre-or postvaccination antibody levels. Antibody response for serotype 6B was better in younger SSc patients on DMARDs (P = 0.019). No significant association between age and antibody response was seen for serotype 23 F. Current smoking did not influence the antibody response. Neither ongoing prednisolone treatment (yes/no) nor prednisolone dose had any impact on the antibody response. The type of SSc disease (diffuse vs limited cutaneous), HAQ or modified Rodnan skin score at vaccination did not significantly influence vaccine response.
Tolerability of the vaccine
Both vaccines were generally well tolerated. Local pain and tenderness at the injection site, increased body temperature for a few days, headache, flu-like symptoms and general sense of illness were the most common side effects. Only one patient described an increased general muscle and joint pain similar to previously experienced symptoms of disease flare. However, these symptoms resolved spontaneously.
Discussion
The present study is the first to report on the immunogenicity and tolerability of two currently licenced pneumococcal vaccines (a polysaccharide and a conjugate one) in adult patients with SSc compared with controls. We demonstrated that the antibody response to two capsular polysaccharide serotypes (6B and 23 F) as well as functionality of antibodies for 23 F in SSc patients not receiving DMARDs was as good as in controls regardless of vaccine type. SSc patients treated with DMARDs, however, had lower proportion of patients with positive antibody response, although the functionality of the antibodies was preserved. These results suggest that immunomodulating drugs but not SSc itself and/or immunological disturbance as a part of this disease affect the ability to produce a sufficient amount of vaccine-specific antibodies, but not their function. In adult individuals with SSc, the PCV13 seems not to be significantly superior to the polysaccharide vaccine. In addition, both vaccines were safe and associated with mild side effects.
Few studies have explored the immunogenicity and tolerability of a pneumococcal vaccine in patients with SSc. In a small study including 18 SSc patients immunized with a dose of PPV23, 83% of participants showed satisfactory antibody response with a 2-fold increase in antibody levels to three or more pneumococcal capsular polysaccharide [10] . Of these, only eight individuals received immunosuppressive treatment (colchicine = 5; D-pen = 1 and CYC = 2), that is, not the standard of care therapy, which may account for the diverging results.
Our study has some important limitations. The immunogenicity of vaccines was determined by measuring antibody response to only two pneumococcal polysaccharides. These serotypes were among the seven common IPD-causing serotypes in the population of Skå ne region, Sweden, found in 436 pneumococcal blood isolates during 200910 [18] . Since we investigated the impact of anti-rheumatic treatment on antibody response, we assumed that ongoing treatment would affect the response to all serotypes in the same way. For the same reason the functionality of serotype-specific antibodies was studied only for one serotype (23 F). In addition, the number of patients receiving DMARD treatment was limited but still sufficient to detect difference in antibody response compared with patients without active anti-rheumatic treatment. Another limitation is that SSc patients on DMARD and those without DMARD were not matched and might have had a slightly different phenotype. Patients on DMARD were likely more often in early stage and had more active disease. However, we did not find any significant impact of type of disease (diffuse or limited cutaneous), HAQ or modified Rodnan skin score on the vaccine response.
In the present study, higher age did not have a convincing negative effect on the ability to generate sufficiently high antibodies levels. These results are in line with previous data confirming satisfactory immunogenicity of both type of vaccine in older adults [19, 20] .
In conclusion, pneumocoocal vaccination is safe and immunogenic in patients with SSc, although treatment with DMARDs may decrease the vaccine-specific antibody response. The currently recommended prime-boost vaccination strategy using a dose of PCV13 followed by a dose of PPV23 might be a possible way of enhancing the vaccine immunogenicity in immunosuppressed patients [3] . 
